חוב לטווח קצר להון עצמי Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals (SLRX) automates the creation of antitumor agents, utilizing AI and robotics to reduce manual labor. The price trend reflected in this chart is accompanied by a critical capital shortage, which calls the business's survival into question due to previous FDA delays. The company currently relies on grants while awaiting profits from the implementation of targeted therapy, with the metric standing at 0.00.

Developing innovative epigenetic cancer therapies, Salarius Pharmaceuticals (SLRX) relies on patents, while the current level of short-term capital load reflects the proportion of liabilities with a maturity of over one year to equity, allowing investors to assess financial stability and default risk when scaling developments without sacrificing commercial margins.